HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis

Emmanuelle Génin(Inserm), D-P Chen(Chang Gung University), Wen‐Hung Chung(National Yang Ming Chiao Tung University), Peggy Sekula(University Medical Center Freiburg), Martin Schumacher(University Medical Center Freiburg), Chang Py(Chang Gung University), Shih‐Hung Tsai(Chang Gung University), T.S. Wu(Chang Gung University), Teresa Bellón(Hospital Universitario La Paz), R Tamouza(Inserm), Catherine Fortier(Inserm), Antoine Toubert(Inserm), Dominique Charron(Inserm), Alain Hovnanian(Inserm), P. Wolkenstein(Inserm), W-H Chung(Chang Gung University), Maja Mockenhaupt(University Medical Center Freiburg), J C Roujeau(Université Paris-Est Créteil)
The Pharmacogenomics Journal
December 10, 2013
10.1038/tpj.2013.40
Cited by 249

Abstract

Related Papers

A marker for Stevens–Johnson syndrome
Wen‐Hung Chung, Wen‐Hung Chung, Hong‐Shang Hong et al.|Nature|2004|1.7k
Clinical Classification of Cases of Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome, and Erythema Multiforme
Sylvie Bastuji‐Garin|Archives of Dermatology|1993|1.6k
Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions
Wen‐Hung Chung, Wen‐Hung Chung, Shiou‐Hwa Jee et al.|Pharmacogenetics and Genomics|2006|670
Carbamazepine, <i>HLA-B*1502</i> and Risk of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: US FDA Recommendations
P. Brent Ferrell, Howard L. McLeod|Pharmacogenomics|2008|416
The Spectrum of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Clinical Classification.
Jean‐Claude Roujeau|Journal of Investigative Dermatology|1994|289